211 results on '"Alana L. Welm"'
Search Results
2. Breast cancer PDxO cultures for drug discovery and functional precision oncology
3. Immunologically 'cold' triple negative breast cancers engraft at a higher rate in patient derived xenografts
4. A Rare Variant in MDH2 (rs111879470) Is Associated with Predisposition to Recurrent Breast Cancer in an Extended High-Risk Pedigree
5. Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research
6. Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
7. An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
8. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models
9. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment
10. Single‐cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing
11. Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway
12. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
13. Author Correction: Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway
14. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
15. Erratum: 'Toward improved models of human cancer' [APL Bioeng. 5, 010901 (2021)]
16. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
17. Toward improved models of human cancer
18. Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
19. A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer
20. Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth
21. The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
22. Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer
23. Data from Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
24. Supplementary Data from Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
25. Supplementary Figures from Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression
26. Table S2 from Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression
27. Data from Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression
28. Data from NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors
29. Supplemental tables and figures from NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors
30. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion
31. Supplementary Figure S2. Cell proliferation inhibition in parental and doxorubicin resistant derivate. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
32. Supplementary Figure S6. Cell proliferation inhibition of cetuximab and FASN inhibitors EGCG and C75 in doxorubicin resistant cells from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
33. Summary of in vivo studies from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
34. Data from Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers
35. Supplementary Figure S5. Cell proliferation inhibition of cetuximab, FASN inhibitor (EGCG or C75) and the combination. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
36. Supplementary Data from Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers
37. Summary of RNA sequencing (RNA seq) data of the Met superfamily kinases in 4 breast PDX models. from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
38. Data from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
39. Supplementary Figure S7. Total volume data for EGCG plus cetuximab in sensitive and resistant TNBC ortoxenograft. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
40. Efficacy of estrogen releasing pellets. from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
41. Supplementary Data from Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer
42. Supplementary Figure S3. FASN and EGFR mRNA levels. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
43. Supplementary Table S1. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
44. Supplementary Figure S4. Cell proliferation inhibition of FASN inhibitors EGCG and C75 in doxorubicin resistant cells from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
45. Data from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
46. Data from Dll1-Mediated Notch Signaling Drives Tumor Cell Cross-talk with Cancer-Associated Fibroblasts to Promote Radioresistance in Breast Cancer
47. Interaction of sfRon and the p85a subunit of PI3K in MCF7-sfRon cells and breast cancer PDX tumors from Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts
48. Supplementary Table 2 from Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response
49. Supplementary Methods, Figures 1-7 from Protein Arginine Methyltransferase 5 Accelerates Tumor Growth by Arginine Methylation of the Tumor Suppressor Programmed Cell Death 4
50. Supplementary Figure 3 from Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.